Filing Flows › Wave Life Sciences (WVE) › Q2 2026
Wave Life Sciences (WVE) Q2 2026 earnings results (second quarter 2026)
10-Q filed Jul 30, 2026
Wave Life Sciences (WVE) reported revenue of $2.3M for the second quarter 2026 (Q2 2026), -74% from a year earlier and -94% from the quarter before.
Wave Life Sciences, Q2 2026: revenue $2.3M (-74% year over year), net loss $69.4M, operating cash flow −$53.6M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.3M | -94% | -74% |
| Operating profit | −$73.8M | — | — |
| Net earnings | −$69.4M | — | — |
| Operating cash flow | −$53.6M | — | — |
What changed
Revenue was $2.3M in Q2 2026, down 74% year over year and down 94% from the previous quarter.
Operating costs exceeded revenue by $73.8M, an operating margin of -3248.3%. Total costs grew 24% against a revenue fall of 74%. The fastest-growing cost line was General & admin (+38%). The quarter ended with a net loss of $69.4M, wider than the previous quarter's $26.1M loss.
Operating cash flow was −$53.6M. Non-cash charges added back $858K of depreciation and $10.7M of share-based compensation. Working capital and other items added $4.2M. Capital expenditures of $884K exceeded it, leaving free cash flow of −$54.5M.
Questions
What was Wave Life Sciences' revenue in the second quarter 2026?
Wave Life Sciences (WVE) reported revenue of $2.3M for the second quarter 2026 (Q2 2026), -74% from a year earlier and -94% from the quarter before.
Source: Wave Life Sciences 10-Q on SEC EDGAR.